We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced an update to its December 8, 2008 press release regarding...
XTLbio Announces Grant of Human Monoclonal Antibody Patent Patent Covers Antibodies Directed Against Hepatitis B Virus Surface Antigen Rehovot, Israel 26 January 2004 - XTL Biopharmaceuticals...
XTLbio appoints Stockbroker and Financial Adviser Rehovot, 20 January 2004 - The Board of XTL Biopharmaceuticals Ltd ("XTLbio" or the "Company") is pleased to announce the appointment of Code...
XTLbio announces appointment of Non-Executive Director Rehovot, 12 January 2004 - XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to announce the appointment of Peter Stalker, III, as a...
RNS Number:2908T XTL Biopharmaceuticals Limited 16 December 2003 XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today...
XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today announces an update on recent clinical progress and corporate developments...
XTLbio Highlights Presence at The Liver Meeting HepeX Programs at 54th Annual AASLD include Poster Presentations, Oral Presentation and Exhibitors Booth Rehovot, Israel, 28 October 2003: XTL...
XTLbio announces appointment of Non-Executive Director Rehovot, Israel, 20 October 2003: XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to announce the appointment of Dr. Hadar Ron as a...
NOTIFICATION OF MAJOR INTERESTS IN SHARES 1) Name of company XTL Biopharmaceuticals Limited 2) Name of shareholder having a major interest Perpetual Income & Growth Investment Trust plc 3) Please...
XTLbio ACQUIRES BROAD RIGHTS FROM STANFORD UNIVERSITY TO ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS (HCV) Exclusive license enhances XTLbio's HepeX-C program in clinical development Rehovot...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 116.6 | 2.5289550167 | 4610.6 | 4746.3 | 4610.6 | 0 | 0 | IX |
| 4 | 93.9 | 2.02663328513 | 4633.3 | 4746.3 | 4550.3 | 0 | 0 | IX |
| 12 | 141.6 | 3.08792742498 | 4585.6 | 4746.3 | 4495.5 | 0 | 0 | IX |
| 26 | 306.3 | 6.92845348232 | 4420.9 | 4746.3 | 4272.8 | 0 | 0 | IX |
| 52 | 721.3 | 18.0059412367 | 4005.9 | 4746.3 | 3971.3 | 0 | 0 | IX |
| 156 | 702.5 | 17.4547171218 | 4024.7 | 4746.3 | 3613.9 | 0 | 0 | IX |
| 260 | 1034.8 | 28.025132705 | 3692.4 | 4746.3 | 2519.3 | 0 | 0 | IX |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
